Search Results

BeiGene, Ltd., a global oncology company, announced the presentation of new data from the SEQUOIA study of BRUKINSA® at the European Hematology Association 2024 Hybrid Congress in Madrid, Spain in an oral session.

Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress.

Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress.

Cytokinetics, Incorporated announced it will host an investor event and conference call on May 13, 2024 at 4:00 PM Western European Summer Time to discuss the primary results from SEQUOIA-HCM, which are being presented in a Late Breaking Clinical Trial session at Heart Failure 2024, an International Congress of the European Society of Cardiology.

Cytokinetics, Incorporated today announced three Late Breaking Clinical Trial presentations relating to SEQUOIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), at Heart Failure 2024, an International Congress of the European Society of Cardiology, taking place in Lisbon, Portugal from May 11, 2024 – May 14, 2024.

Cytokinetics, Incorporated announced positive topline results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy.

Cytokinetics, Incorporated announced that the baseline characteristics of patients randomized in SEQUOIA-HCM, the pivotal Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy, were presented at the HCM Society Scientific Sessions in Cleveland, Ohio by Martin S. Maron, M.D., Director of the Hypertrophic Cardiomyopathy Center at Lahey Hospital and Medical Center.